Form 4: Avidity Biosciences Executive Exercises Options and Sells Shares

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, exercised stock options to acquire 5,875 shares of common stock on February 3, 2025, at a price of $16.65 per share.
• On the same day, Gallagher sold 5,875 shares of common stock at a weighted-average price of $32.1563, with individual sales ranging from $31.53 to $32.77.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Gallagher directly owns 50,554 shares of Avidity Biosciences common stock and holds options for 34,675 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice in the biotechnology industry.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which are also focused on RNA therapeutics, see similar filings from their executives.
• The use of Rule 10b5-1 trading plans is a standard method for insiders to manage their stock transactions while avoiding accusations of trading on non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates